MIAMI, May 23 /PRNewswire/ -- Cordis Corporation today announced the appointment of Campbell Rogers, M.D., to the position of Chief Technology Officer (CTO), effective early July. In this newly created role, Dr. Rogers will direct the company’s scientific and technical agenda and lead investments and research in innovative cardiovascular and peripheral vascular technologies.
“We are thrilled to have Dr. Rogers join the Cordis family,” said Rick Anderson, Company Group Chairman, Johnson & Johnson and Worldwide Franchise Chairman, Cordis Corporation. “His experience and expertise in interventional cardiology and vascular health will contribute significantly to the next stage in the company’s growth, and with his leadership and talents, we will continue to serve the needs of the millions of patients globally with cardiac and vascular conditions.”
Dr. Rogers was most recently Associate Professor of Medicine, Harvard Medical School in Cambridge, Mass., and Director, Cardiac Catherization Laboratory (CCL), Cardiovascular Division, Brigham and Women’s Hospital in Boston, Mass. He was responsible for overseeing all aspects of CCL activity, including faculty practice, clinical care, medical student, resident and cardiology fellow education, and clinical research.
As Principal Investigator of Brigham and Women’s comprehensive interventional vascular biology laboratory, Dr. Rogers has led work utilized for clinician education worldwide on the use of novel devices preceding clinical application. He also has extensive experience as a National Principal Investigator and Co-investigator of multi-center device and pharmacologic trials based in the cardiac catheterization lab.
“I look forward to joining the Cordis team,” said Dr. Rogers. “The company has been at the forefront of innovation, education and clinical evidence for decades and I am honored to now be part of the company’s mission to defeat cardiac and vascular diseases.”
Dr. Rogers is the author of numerous journal articles in the area of cardiovascular disease and is the recipient of many academic society honors. He has also been a visiting physician to various institutions in Beijing, China, Brazil, and Hong Kong.
Dr. Rogers graduated from Harvard College, attended Clare College in Cambridge, England and received his medical degree from Harvard Medical School. In addition to his position at Brigham and Women’s Hospital, he has been a Clinical Associate, Massachusetts General Hospital and served as a Research Associate, Veteran’s Administration Medical Center in Massachusetts.
The appointment of a new CTO represents a significant milestone in the history of Cordis Corporation. Innovation and convergent technology is the future of the medical device industry and this new position places Cordis at the forefront of developing breakthrough technologies in drug, device and information device concepts.
“Dr. Rogers’ extensive experience in medical device technology, drug development and clinical expertise, coupled with his management experience, and his experience working directly with patients to advance cardiovascular care make him uniquely qualified for this position,” said Mr. Anderson.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company’s innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.
Cordis Corporation
CONTACT: Christopher Allman of Cordis Cardiology, (O) +1-786-313-2303, (M)+1-305-586-6024, Email: Callman1@crdus.jnj.com; or Todd Ringler of Edelman,(O) +1-617-872-1235, Email: Todd.ringler@edelman.com
Web site: http://www.cordis.com/
